# US 2015/0031727 A1 · Aminoalkyl-substituted n-thienylbenzamide derivative

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0031727 A1
- Document ID: US20150031727A1
- Status: Published application
- Kind: A1
- Application number: 14/354,086
- Filed: 2012-10-25
- Published: 2015-01-29
- Earliest claimed: 2011-10-27
- Assignees: Astellas Pharma Inc.
- Applicants: Astellas Pharma Inc.
- Inventors: Masanori Miura; Daisuke Kaga; Susumu Watanuki; Shunichiro Hachiya; Takao Okuda; Ippei Sato; Mai Isomura; Kazuhiro Terai; Yoh Terada
- Web page: https://patentgrep.com/patent/US20150031727A1

## CPC

- C07D 409/12: linked by a chain containing hetero atoms as chain links
- A61P 3/12: for electrolyte homeostasis
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 13/12: of the kidneys
- A61P 19/00: Drugs for skeletal disorders
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 333/68: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 333/78: condensed with rings other than six-membered or with ring systems containing such rings
- C07D 333/80: Seven-membered rings
- C07D 409/14: containing three or more hetero rings
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 453/02: containing not further condensed quinuclidine ring systems
- C07D 495/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

[Problem] To provide a compound that has an intestinal phosphate transporter (NPT-IIb) inhibitory action and is useful as an active ingredient of an agent for treating and/or preventing hyperphosphatemia. [Means for Solution] The present inventors conducted their studies on a compound that has an NPT-IIb inhibitory action and is useful as an active ingredient of an agent for treating and/or preventing hyperphosphatemia. As a result, they created an aminoalkyl-substituted N-thienylbenzamide derivative which has NPT-IIb inhibitory action, thereby completing the present invention. The aminoalkyl-substituted N-thienylbenzamide derivative of the present invention has an NPT-IIb inhibitory action and can be used as an agent for preventing and/or treating hyperphosphatemia.

## Claims

### Claim 1

A compound of formula (I) or a salt thereof, or hydrate thereof,
wherein:
X1 represents CH2 or O;
k represents 1, 2, or 3;
R3 represents H or lower alkyl;
X2 represents CH or N;
L1 represents lower alkylene;
R1 represents H or lower alkyl;
X3 represents CH or N;
L2 represents lower alkylene;
R5 represents H or lower alkyl;
R6 represents H, lower alkyl, lower alkyl substituted with one to two of —OR0, —C(O)-lower alkyl, —S(O)m-lower alkyl, -lower alkylene-N(lower alkyl)2, —R00-heterocycle, —R00-phenyl, or —R00-cycloalkyl, wherein the heterocycle, phenyl and cycloalkyl may be substituted with one to two lower alkyl or C(O)-lower alkyl, and —R00 may be substituted with one —OR0, wherein
R00 represents a bond or lower alkylene,
R0 represents H or lower alkyl, and
m represents 0, 1, or 2;
L3 represents lower alkylene;
n represents 0 or 1;
R4 represents H, lower alkyl, -lower alkylene-COO—R0, -lower alkylene-OR0, -lower alkylene-NHR0, -lower alkylene-N(lower alkyl)2, or cycloalkyl;
L4 represents a bond, 0, or —NR0—;
Y represents —R00-monocyclic heterocycle-R00—, —R00-phenyl-R00—, -lower alkylene-NR0-lower alkylene-, lower alkylene-O-lower alkylene-, or lower alkylene which may be substituted with a hydroxyl group; and,
R2 represents H or lower alkyl.

### Claim 2 (depends on 1)

The compound or a salt thereof or hydrate thereof according to claim 1, wherein in formula (I), R6 represents lower alkyl or cycloalkyl.

### Claim 3 (depends on 2)

The compound or a salt thereof or hydrate thereof according to claim 2, wherein in formula (I), n represents 1, and R4 represents H, lower alkyl, or lower alkylene-OR0.

### Claim 4 (depends on 3)

The compound or a salt thereof or hydrate thereof according to claim 3, wherein in formula (I), Y represents lower alkylene which may be substituted with a hydroxyl group.

### Claim 5 (depends on 4)

The compound or a salt thereof or hydrate thereof according to claim 4, wherein in formula (I), X1 represents CH2, and k represents 1.

### Claim 6 (depends on 5)

The compound or a salt thereof or hydrate thereof according to claim 5, wherein in formula (I), both the X2 and X3 represent CH.

### Claim 7 (depends on 1)

The compound of claim 1, wherein said compound is selected from the group consisting of:
4-(2-{4-[({2-[(3-{[{2-[(3-carboxypropanoyl)(methyl)amino]ethyl}(pentan-3-yl)amino]methyl}benzoyl)amino]-4,5,6,7-tetrahydro-1-benzothiophen-3-yl}carbonyl)amino]phenyl}ethyl)benzoic acid;
4-(2-{4-[({2-[(3-{[{2-{[(carboxymethoxy)carbonyl](methyl)amino}ethyl)
(pentan-3-yl)amino]methyl}benzoyl)amino]-4,5,6,7-tetrahydro-1-benzothiophen-3-yl}carbonyl)amino]phenyl}ethyl)benzoic acid;
4-(2-{4-[({2-[(3-{[{2-[(4-carboxy-4-methylpentanoyl)(methyl)amino]ethyl}(pentan-3-yl)amino]methyl}benzoyl)amino]-4,5,6,7-tetrahydro-1-benzothiophen-3-yl}carbonyl)amino]phenyl}ethyl)benzoic acid;
4-(2-{4-[({2-[(3-{[{3-[(3-carboxypropanoyl)(methyl)amino]propyl}(pentan-3-yl)amino]methyl}benzoyl)amino]-4,5,6,7-tetrahydro-1-benzothiophen-3-yl}carbonyl)amino]phenyl}ethyl)benzoic acid;
4-(2-{4-[({2-[(3-{[{2-[(3-carboxypropanoyl)(2-methoxyethyl)amino]ethyl}(pentan-3-yl)amino]methyl}benzoyl)amino]-4,5,6,7-tetrahydro-1-benzothiophen-3-yl}carbonyl)amino]phenyl}ethyl)benzoic acid;
4-(2-{4-[({2-[(3-{[(4-carboxy-4-methylpentanoyl)(pentan-3-yl)amino]methyl}benzoyl)amino]-4,5,6,7-tetrahydro-1-benzothiophen-3-yl}carbonyl)amino]phenyl}ethyl)benzoic acid; and
4-(2-{4-[({2-[(3-{[(4-carboxy-3,3-dimethylbutanoyl)(pentan-3-yl)amino]methyl}benzoyl)amino]-4,5,6,7-tetrahydro-1-benzothiophen-3-yl}carbonyl)amino]phenyl}ethyl)benzoic acid, or a salt thereof, or hydrate thereof.

### Claim 8 (depends on 7)

A pharmaceutical composition, comprising:
the compound or a salt thereof or hydrate thereof according to claim 7; and
a pharmaceutically acceptable excipient.

### Claim at position 9

9-11. (canceled)

### Claim 12 (depends on 7)

A method of preventing or treating hyperphosphatemia, the method comprising:
administering an effective amount of the compound or a salt thereof or hydrate thereof according to claim 7 to a subject in need thereof.

### Claim 13 (depends on 7)

The compound of claim 7, wherein said compound is 4-(2-{4-[({2-[(3-{[{2-[(3-carboxypropanoyl)(methyl)amino]ethyl}(pentan-3-yl)amino]methyl}benzoyl)amino]-4,5,6,7-tetrahydro-1-benzothiophen-3-yl}carbonyl)amino]phenyl}ethyl)benzoic acid, or a salt thereof, or hydrate thereof.

### Claim 14 (depends on 7)

The compound of claim 7, wherein said compound is magnesium 4-(2-{4-[({2-[(3-{[{2-[(3-carboxylatopropanoyl)(methyl)amino]ethyl}(pentan-3-yl)amino]methyl}benzoyl)amino]-4,5,6,7-tetrahydro-1-benzothiophen-3-yl}carbonyl)amino]phenyl}ethyl)benzoate, or hydrate thereof.

### Claim 15 (depends on 7)

The compound of claim 7, wherein said compound is 4-(2-{4-[({2-[(3-{[{2-{[(carboxymethoxy)carbonyl](methyl)amino}ethyl)(pentan-3-yl)amino]methyl}benzoyl)amino]-4,5,6,7-tetrahydro-1-benzothiophen-3-yl}carbonyl)amino]phenyl}ethyl)benzoic acid, or a salt thereof, or hydrate thereof.

### Claim 16 (depends on 7)

The compound of claim 7, wherein said compound is 4-(2-{4-[({2-[(3-{[{2-[(3-carboxypropanoyl)(2-methoxyethyl)amino]ethyl}(pentan-3-yl)amino]methyl}benzoyl)amino]-4,5,6,7-tetrahydro-1-benzothiophen-3-yl}carbonyl)amino]phenyl}ethyl)benzoic acid, or a salt thereof, or hydrate thereof.

### Claim 17 (depends on 7)

The compound of claim 7, wherein said compound is magnesium 4-(2-{4-[({2-[(3-{[{2-{[(carboxylatomethoxy)carbonyl](methyl)amino}ethyl)(pentan-3-yl)amino]methyl}benzoyl)amino]-4,5,6,7-tetrahydro-1-benzothiophen-3-yl}carbonyl)amino]phenyl}ethyl)benzoate, or hydrate thereof.
